[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palliative-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palliative-care":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,54,0,25,[9,42,67,97,127,152,181,212,233,258,290,313,342,374,398,418,447,473,499,522,543,565,588,611,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635457","management-of-dyspnea-with-high--flow-nasal-therapy-100635457",false,"NCT07552935","Management of Dyspnea With High- Flow Nasal Therapy","HFNTpal","Inclusion Criteria:\n\n* The patient is in palliative care (ICD-10 diagnostic code Z51.5 palliative care)\n* Age ≥ 18 years\n* Ability to understand the study and provide informed consent to participate\n* Significant breathlessness (NRS = Numeric Rating Scale ≥ 4).\n* The treating physician has assessed that the patient would not benefit from treatment in intensive care unit or monitor unit.\n* The treating physician has assessed that the patient would not benefit from invasive mechanical ventilation (intubation) or cardiopulmonary resuscitation.\n\nExclusion Criteria:\n\n* Decreased level of consciousness, delirium, or other lack of cooperation that prevents participation.\n* Respiratory support other than HFNT is required.\n* The patient has received HFNT during the same admission to palliative care ward or hospice.\n* The cause of dyspnea can be treated immediately.\n* Inability to provide informed consent to participate.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Dyspnea in patients with incurable illness is a difficult symptom. Therefore, there is a need to identify new effective treatment modalities. Previous studies suggest that high-flow nasal therapy delivered via a nasal cannula (HFNT = High-Flow Nasal Therapy) may alleviate dyspnea, and similarly that directing airflow toward the face can provide relief. HFNT has been studied very little in hospice settings and on palliative care wards. The aim of this study is to determine whether HFNT is a feasible and effective treatment for relieving dyspnea in patients receiving palliative care.\n\nPatients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland. The target is to recruit approximately 30-40 patients. The inclusion criteria are: age ≥18 years, ability to understand the study and provide informed consent to participate, a palliative treatment approach, and significant dyspnea.\n\nEach patient receives HFNT and fan therapy in which airflow will be directed toward the patient's face. Both treatments will last 30 minutes. Patient symptoms will be asked after the treatments. In addition, patients will be asked to rate the overall benefit they experienced from the intervention and any side effects. The primary endpoint is the relief of dyspnea with HFNT compared with fan therapy.\n\nThe study will be conducted in accordance with laws, regulations, and guidelines governing medical research, as well as good scientific practice and research ethics. The study does not involve significant risks or measurements or sampling procedures that would cause additional discomfort. All other care for the patient will be provided according to the standard practices of the treating unit, and participation in the study will not limit any necessary treatments. Identifiable information will not be disclosed for use outside the research group. Results will be reported in a manner that does not allow patients to be identified. The Ethics Committee of the Wellbeing Services County of Pirkanmaa has approved the study.\n\nIf successful, the study will significantly improve the care of the patients in palliative care.",[27,28],"Palliative Care","Breathlessness","RECRUITING","2026-06-25",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-06-01",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"Tampere University Hospital","OTHER",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100644990","oncologic-timely-palliative-care-and-remote-monitoring-with-electronic-assessments-and-telehealth-on-target-100644990","NCT07674797","Oncologic Timely Palliative Care And Remote Monitoring With Electronic Assessments And Telehealth (ON-TARGET)","Eligibility Criteria\n\n* Age ≥ 18\n* Outpatients who are within 12 weeks of diagnosis of metastatic solid tumors and seen by one of the participating medical oncologists\n* Eastern Cooperative Oncology Group Performance Status 0.2\n* Able to speak English or Spanish\n\nExclusion Criteria:\n\n. Cognitive impairment in the opinion of the oncologist necessitating need for a surrogate decision making.\n\n• Previously seen by SPC team at UT MD Anderson",{"count":49,"type":21},300,[24],"To examine how we can provide supportive care for patients with advanced cancer better tailored to their needs",[53,27,54,55,56],"Oncologic","Remote Monitoring","Electronic Assessments","Telehealth","NOT_YET_RECRUITING","2026-06-24",{"date":32,"type":33},{"date":61,"type":21},"2026-11-22",{"date":63,"type":21},"2034-06-30",{"name":65,"class":40},"M.D. Anderson Cancer Center",1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":66},"100642152","mobile-health-application-for-family-caregivers-in-home-palliative-care-100642152","NCT07654998","Mobile Health Application for Family Caregivers in Home Palliative Care","Effectiveness of a Mobile Health Application for Family Caregivers of Patients Receiving Home Palliative Care: A Randomized Controlled Trial","CARE-Mobile","Inclusion Criteria:\n\n* Family caregiver of a patient receiving home palliative care services.\n* Aged 18 years or older.\n* Providing unpaid care to the patient for at least 3 months.\n* Able to read and understand Turkish.\n* Owns or has regular access to a smartphone compatible with the mobile application.\n* Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Professional or paid caregivers.\n* Participation in another structured caregiver support program during the study period.\n* Cognitive, visual, or hearing impairments that would prevent effective use of the mobile application.\n* Inability to complete study assessments.\n* Withdrawal of consent at any stage of the study.",{"count":76,"type":21},120,[24],"Family caregivers play a central role in providing daily care for patients receiving home palliative care. However, caregiving responsibilities may lead to increased burden, stress, and difficulties in symptom management and care coordination. Mobile health (mHealth) interventions may provide accessible education, symptom monitoring, and decision-support resources to improve caregiver outcomes and patient care.\n\nThe aim of this randomized controlled trial is to evaluate the effectiveness of a mobile health application developed for family caregivers of patients receiving home palliative care. The primary outcome is caregiver competence. Secondary outcomes include caregiver burden, self-efficacy, patient symptom burden, emergency department visits, and hospitalizations.\n\nA total of 120 family caregivers will be randomly assigned to either the intervention group, which will use the mobile health application for 6 weeks in addition to usual care, or the control group, which will receive usual care alone. Outcomes will be assessed at baseline, post-intervention (Week 6), and follow-up (Week 18).",[27,80,81],"Cancer","Caregiver",[83,84,85,86,87],"Mobile Health","Family Caregiver","Home Palliative Care","Caregiver Competence","Caregiver Burden","2026-06-23",{"date":90,"type":33},"2026-06-26",{"date":92,"type":21},"2026-06-10",{"date":94,"type":21},"2026-10-30",{"name":96,"class":40},"Kutahya Health Sciences University",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":66},"100249200","phase-1-periganglionic-resiniferatoxin-for-the-treatment-of-intractable-pain-due-to-cancer-induced-bone-pain-100249200","NCT02522611","Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","-INCLUSION CRITERIA:\n\n1. Male or female subjects must be at least 18 years of age or older.\n2. Must be diagnosed with histologically-confirmed cancer-induced bone pain producing intractable chronic pain in the target area (mid thoracic or chest level down to lower extremities) which was poorly responsive to conservative therapies based on patient report, such as analgesic medication management with potent opioids with or without prior radiotherapy, bisphosphonates, or radioisotope therapy. Additionally, pain that is non-responsive to non-opioid drugs in situations where opioids were not tolerated. Conservative therapies do not include invasive treatments, such as neurolytic procedure, including surgical neurolysis, percutaneous regional or neuraxial continuous infusions (whether opioid or local anesthetic), and peripheral neuromodulation or spinal cord stimulation, but may include temporary diagnostic or therapeutic procedures.\n3. Not currently seeking or receiving potentially curative therapies for cancer (e.g., chemotherapy or immunotherapy). Curative cancer therapy may be sought after the Outpatient Follow Up visit 14 (D14). Palliative anti-tumor therapy is allowed as long as the subject was established on that therapy prior to enrollment.\n4. Must have moderate to severe pain that is not relieved by standard treatments. Mean daily worst pain NRS score of greater than or equal to 6 for pain at or below the T6 dermatome (level of the chest) that is associated with a malignant disease. The mean score must be derived from recordings on at least 4 of 7 consecutive days within 3 weeks preceding treatment.\n5. The subject must agree to undergo a diagnostic periganglionic injection(s) with a long-acting local anesthetic (e.g., bupivacaine) under fluoroscopic guidance which resulted in at least a 30% temporary pain reduction in the targeted pain region lasting for the expected duration of the local anesthetic used.\n6. Must be healthy enough to tolerate study procedures in the judgment of the investigator.\n7. Subjects taking aspirin, non-steroidal anti-inflammatory medications, or vitamin supplements that include vitamin E or any prophylactic anticoagulant (including but not limited to Coumadin, heparin, or Xarelto) will be counseled either to stop taking these at least 7 days before surgery or be given instructions on dosing changes if applicable. In addition, if patients are currently taking a Factor Xa inhibitor (such as Xarelto) a hematology consult will be obtained. Subjects must be willing to comply with this requirement, which is standard clinical practice when undergoing elective surgical procedures to avoid surgical and post-surgical bleeding complications.\n8. Formal review of the subject s medical records and written approval for his\u002Fher inclusion in the study by 3 separate persons:\n\n   * Principal Investigator (PI) or an Associate Investigator (AI).\n   * Medical oncologist or oncologic surgeon.\n   * A member of the Pain and Palliative Care Service (PPCS) at the NIH.\n9. For women of childbearing potential and men with partners of childbearing potential, the ability and willingness use an effective method of contraception during the study.\n\n   Effective methods of birth control include:\n   * hormonal contraception (birth control pills, injected hormones, or vaginal ring).,\n   * intrauterine device.\n   * barrier methods (condom or diaphragm) combined with spermicide\n   * surgical sterilization (hysterectomy, tubal ligation, or vasectomy).\n10. Medical clearance from referring physician consisting of a statement indicating an adequate recovery period from other previous trials\u002Fmedication if known.\n11. Must be able and willing to undergo an eye examination.\n12. Must be able to read, speak and understand English and willing to complete the study tools and forms.\n13. Subjects must have provided written informed consent which includes signing the institutional review board (IRB)-approved consent form prior to participating in any study-related activity.\n14. Must have the capacity to provide informed consent.\n15. Must have a responsible adult to provide assistance with activities of daily living as needed for the subject through the Day 14 visit.\n16. Must have abilityAbility to assign a Durable Power of Attorney (DPA) for research and medical care at NIH.\n\nEXCLUSION CRITERIA:\n\nSubjects will be excluded from the study if they meet any of the following criteria:\n\n1. Subject must not have primary pain source from anatomical regions at T5 dermatome or above.\n2. Subject must not have pain due to causes other than cancer or its treatment that is moderate to severe in intensity.\n3. Subjects must not be undergoing or have plans to undergo any active treatment for their cancer during the study until after the day 14 assessment timepoint, after the RTX injection.\n4. Subject must not be anticipating initiation of palliative anti-tumor therapy or significant changes to current palliative anti-tumor therapy before completion of the Day 14 visit.\n5. Subject must not have an ECG abnormality of which the baseline QTc interval exceeds 450 milliseconds.\n6. Subjects must not have an allergy or hypersensitivity to chili peppers, capsaicin or radiographic contrast agents.\n7. Subject must not have an anatomic abnormality or pathology of the spinal cord and\u002For PG space on magnetic resonance imaging (MRI) that could increase the risk of adverse effects of placement of the needle.\n8. Subject must not have a contraindication to MRI or MRI contrast..\n9. Subjects must not have evidence of a coagulopathy or hemostasis problem as\n\n   evidenced by the following blood laboratory values within the week prior to the planned injection:\n   * PT\u002FINR (prothrombin time\u002FInternational normalized ratio) \\> 1.5 times upper limit of normal range (ULN).\n   * PTT (partial thromboplastin time) \\> 35 seconds.\n10. Subjects must not have a platelet count \\\u003C50,000\u002Fmm3. Platelets will be transfused as necessary to raise the platelet count to greater than or equal to 100,000\u002Fmm3 prior to dosing.\n11. Subjects must not have a total neutrophil count (TNC) \\\u003C1500. The US Clinical Practice Guideline for lumbar puncture is a platelet count of 50,0000, which is higher risk for hemorrhage than periganglionic infection. Patients with TNC\\\u003C1500 (neutropenia) may be eligible later if their TNC level becomes greater than 1500 spontaneously or after use of medications stimulating granulocyte production, such as Neupogen (granulocyte colony stimulating factor: G-CSF).\n12. Subjects must not have abnormal electrolyte levels (i.e. low potassium) that cannot be corrected.\n13. Subjects must not be febrile or have other evidence of an infection within 7 days of the planned periganglionic injection.\n14. Subjects must not have an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.\n15. Female subjects must not be pregnant or breastfeeding.\n16. Subjects with any medical condition that, in the Investigator s opinion, could adversely impact the subject s participation or safety, conduct of the study, or interfere with the pain assessment, such as poorly controlled diabetes or hypertension. Patients can be re-assessed for eligibility if these conditions can be controlled medically.\n17. Subjects may not have a history of heart failure or unexplained fainting (syncope).\n18. Subjects may not have a known family history of long QT syndrome.\n19. Subjects who participated in a clinical trial of an investigational drug or device within 30 days of screening visit or are scheduled to receive an investigational product within 14 days of RTX injection.\n20. Subjects must not have received invasive treatments, such as a neurolytic procedure, including surgical neurolysis, percutaneous regional or neuraxial continuous infusions (whether opioid or local anesthetic), peripheral neuromodulation or spinal cord stimulation.","99 Years",{"count":106,"type":21},30,[108,109],"PHASE1","PHASE2","Background:\n\nCancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and quality of life. Researchers believe a research drug called resiniferatoxin (RTX) may be able to help.\n\nObjective:\n\nTo learn whether RTX is safe and can reduce cancer induced bone pain.\n\nEligibility:\n\nPeople ages 18 and older with CIBP that is not relieved by standard treatments\n\nDesign:\n\nParticipants will have up to 6 outpatient visits over about 7 months. These will include:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests.\n\nThermal testing: a disk placed on the skin to test ability to sense temperature in and around the area of pain\n\nChest x-ray\n\nEKG: stickers are placed on the chest to measure heart signals\n\nECG: measures electrical activity of the heart\n\nParticipants will have 1 inpatient visit lasting 2-4 days. This will include:\n\nCatheter inserted into a vein in the arm. They are given anesthesia, sedation, and x-ray contrast.\n\nA needle is passed through the skin of the back to inject the RTX.\n\nParticipants will keep a log of the pain medications they take after surgery.\n\nParticipants will be called 1 week and 2, 3, and 4 months after the injection.\n\nParticipants will be mailed surveys and questionnaires to complete 2, 3, and 4 months after the injection.",[112,27],"Intractable Pain",[27,114,115,116],"Adults","Cancer Pain","Quality of Life","2026-06-13",{"date":119,"type":33},"2026-06-16",{"date":121,"type":21},"2026-06-27",{"date":123,"type":21},"2026-12-01",{"name":125,"class":126},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":66},"100118154","phase-1-resiniferatoxin-to-treat-severe-pain-associated-with-advanced-cancer-100118154","NCT00804154","Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer","A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer","* INCLUSION CRITERIA:\n\nSubject inclusion criteria are based on inadequate control of pain despite best efforts, including appropriate use of analgesic medications. To be enrolled in the study, subjects must meet all of the following criteria:\n\n1. Age 18 years or older.\n2. Clinical and histological diagnosis of cancer with disease that has not adequately responded to standard therapies. A pathology report documenting malignancy is required.\n3. Subject not currently seeking or receiving potentially curative therapies for cancer (e.g., chemotherapy or immunotherapy). Curative cancer therapy may be sought after the Day 15 clinic visit, and palliative anti-tumor therapy is allowed as long as the subject was established on that therapy prior to enrollment (see exclusion criterion 6).\n4. Mean daily worst pain NRS score of greater than or equal to 6 for pain at or below the T6 dermatome (level of the chest) that is associated with a malignant disease. The mean score must be derived from recordings on at least 4 of 7 consecutive days within 3 weeks preceding treatment.\n5. Alternative methods of pain control are not sufficiently effective, not indicated, not tolerated, and\u002For refused by the subject, as determined by the Pain and Palliative Care Service (PPCS). Alternative methods of pain control include, but are not limited to, the following:\n\n   -Opioids (all routes of administration including neuraxial infusions)\n\n   -Adjuvant pain medications such as antidepressants, corticosteroids, local anesthetics, and antiseizure medications\n\n   -Procedures such as catheter or implantable pump placement for delivery of analgesic medication\n   * Prior neurolytic interventions (including intercostal, superior hypogastric, or celiac plexus blocks)\n   * Complementary medicine approaches\n   * Transcutaneous electric nerve stimulation\n   * Radiation therapy\n6. Reasonable expectation that the subject will be able to complete the study through the 30-day follow-up.\n7. Medical clearance from referring physician consisting of a statement indicating an adequate recovery period from other previous trials\u002Fmedication.\n8. Formal review of the subject s medical records and written approval for his\u002Fher inclusion in\n\nthe study by 3 separate persons:\n\n* Principal Investigator (PI) or an Associate Investigator (AI)\n* Medical oncologist or oncologic surgeon.\n* A member of the PPCS at the NIH or institution s equivalent at other sites.\n\n  10\\. International normalized ratio (INR; from prothrombin time \\[PT\\]) \\\u003C 1.5 and partial thromboplastin time (PTT) less than or equal to the upper limit of the reference range. The INR and PTT may be corrected (e.g., by administration of blood products, vitamin K, etc.), provided a repeat blood draw confirms that the values meet this inclusion criterion.\n\n  10\\. Platelet count greater than or equal to 50,000\u002Fmm\\^3. Platelets will be transfused as necessary to raise the platelet count to greater than or equal to 100,000\u002Fmm\\^3 prior to dosing.\n\n  11\\. Ability to stop any anticoagulant (e.g., Coumadin) and antiplatelet therapies (e.g., aspirin) before and during IT catheter placement according to accepted medical guidelines.1\n\n  12\\. Ability and willingness to undergo an eye examination.\n\n  13\\. Ability to read, speak, and understand English, and willingness to complete the study tools and forms.\n\n  14\\. For women of childbearing potential and men with partners of childbearing potential, the ability and willingness to use an effective method of contraception during the study. Effective methods of birth control include:\n* hormonal contraception (birth control pills, injected hormones, or vaginal ring),\n* intrauterine device,\n* barrier methods (condom or diaphragm) combined with spermicide, or\n* surgical sterilization (hysterectomy, tubal ligation, or vasectomy).\n\n  15\\. Availability of a responsible adult to assist with activities of daily living as needed for the subject through the Day 15 visit.\n\n  16\\. Ability to assign a Durable Power of Attorney (DPA) for research and medical care at NIH\n\nEXCLUSION CRITERIA:\n\nSubjects will be excluded from the study if they meet any of the following criteria:\n\n1. Primary pain source from anatomical regions at T5 dermatome or above.\n2. Pain due to causes other than cancer or its treatment that is moderate to severe in intensity.\n3. Anatomic abnormality or pathology of the spinal cord and\u002For IT space on magnetic resonance imaging (MRI) that could increase the risk of adverse effects of catheter placement or interfere with CSF flow.\n4. Evidence of advanced brain pathology or elevated intracranial pressure as determined by symptoms, history, physical examination (including neurological and eye examination), and\u002For MRI.\n5. Presence of an IT shunt device (e.g., ventriculo-peritoneal and ventriculo-atrial shunts).\n6. Anticipating initiation of palliative anti-tumor therapy or significant changes to current palliative anti-tumor therapy before completion of the Day 15 visit.\n7. Documented allergy to chili peppers or capsaicin (e.g., hives, wheal).\n8. Contraindication to MRI or MRI contrast.\n9. Female subjects who are pregnant or lactating.\n10. Clinically significant disorder or condition that might interfere with study participation or greatly increase safety risk to the subject, as judged by a study investigator.\n11. Planned use of another investigational agent, therapy, or device within 30 days after dosing.\n12. Have a history of heart failure or unexplained fainting (syncope).\n13. Have an EKG abnormality in which the baseline QTc interval exceeds 450 milliseconds.\n14. Have a known family history of long QT syndrome.\n15. Have abnormal electrolyte levels (i.e., low potassium) that cannot be corrected.\n16. Have urinary retention that does not resolve with medical or surgical treatment.\n17. Have skin ulceration that does not resolve with medical or surgical treatment.\n18. Have a history of seizure activity in the previous month.\n19. Have experienced symptoms of opioid toxicity in the past month (i.e. myoclonus, seizures, and\u002For hallucinations)",{"count":135,"type":21},45,[108],"This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chemical extracted from a cactus-like plant. It is similar to capsaicin, the active ingredient in hot pepper. RTX has relieved pain and reduced the need for pain medication in several animal experiments. It works by destroying nerves that transmit pain information.\n\nPeople at least 18 years of age with severe pain from advanced cancer at or below the level of the chest that cannot be controlled with standard treatments may be eligible for this study. Participants undergo the following procedures:\n\nPretreatment Visit\n\nBefore beginning treatment with RTX, patients give a medical history and undergo a physical examination that includes:\n\n* Electrocardiogram (EKG)\n* Blood draw\n* Urinalysis\n* Neurological examinations\n* Peak expiratory flow rate (PEFR)\n* Eye examination\n* MRI\n* Urology assessment\n* Pregnancy test, when appropriate\n* Questionnaires to collect information on health, personality, mood, pain levels and symptoms.\n\n  2-Day Hospitalization\n\nPatients are hospitalized for 2 days for RTX injection and monitoring, as follows:\n\n* RTX injection: RTX is injected in the operating room under general anesthesia. It is given through a catheter placed in the patient s spine. The catheter is also used to obtain samples of cerebrospinal fluid (CSF) the clear fluid that bathes the spinal cord. The fluid is examined to assess drug effects and side effects, chemical changes in the content of the CSF associated with RTX, and how RTX is handled by the body.\n* Post-injection monitoring, including:\n* Surveys about symptoms such as pain or weakness\n* Neurological examinations\n* Blood and CSF sampling\n* EKG\n* AEs\n\nOutpatient followup\n\n* Vitals\n* Blood draw, Urinalysis, neurological and sensory testing, EKG on days 7, 14 and 30 after the injection\n* MRI scans of the head and back, Urology assessment and PEFR on day 15 after the injection\n* Eye examination\n* Follow-up phone calls monthly for 6 months",[112,27],[140,141,115,142],"Vanilloid","Capsaicin","Nerve Block","2026-06-05",{"date":145,"type":33},"2026-06-08",{"date":147,"type":33},"2009-08-14",{"date":149,"type":21},"2027-02-07",{"name":151,"class":126},"National Institute of Dental and Craniofacial Research (NIDCR)",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":66},"100643619","nurse-led-caregiver-support-program-in-home-palliative-care-100643619","NCT07593729","Nurse-Led Caregiver Support Program in Home Palliative Care","Effect of a Nurse-Led Caregiver Support Program on Caregiver Competency and Healthcare Utilization Among Family Caregivers in Home Palliative Care: A Randomized Controlled Trial","CARE-PAL","Inclusion Criteria:\n\n* Adult family caregivers of patients receiving home palliative care services\n* Age 18 years or older\n* Being the primary caregiver responsible for the patient's daily care\n* Ability to communicate in Turkish\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Professional or paid caregivers\n* Caregivers with severe cognitive impairment or severe psychiatric disorders\n* Inability to participate in follow-up assessments",{"count":161,"type":21},150,[24],"This randomized controlled trial aims to evaluate the effect of a nurse-led caregiver support program on caregiver competency and healthcare utilization among family caregivers of patients receiving home palliative care. Family caregivers in the intervention group will receive a structured 6-week nurse-led support program including face-to-face education, weekly telephone coaching, caregiver guidance materials, and decision support for symptom management and healthcare utilization. The control group will continue to receive routine home palliative care services. Primary outcome is caregiver competency. Secondary outcomes include caregiver burden, self-efficacy, patient symptom burden, emergency department visits, and hospitalizations.",[27,87,165],"Home Care",[167,168,169,170,171,172,173],"Nurse-led intervention","Family caregiver","Caregiver competency","Home care","Randomized controlled trial","Palliative care","Healthcare utilization","2026-06-04",{"date":145,"type":33},{"date":177,"type":21},"2026-05-12",{"date":179,"type":21},"2026-09-30",{"name":96,"class":40},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100637389","the-effect-of-progressive-muscle-relaxation-and-deep-breathing-exercises-applied-to-palliative-care-cancer-patients-on-dyspnea-fatigue-and-self-care-behaviors-100637389","NCT07619209","The Effect of Progressive Muscle Relaxation and Deep Breathing Exercises Applied to Palliative Care Cancer Patients on Dyspnea, Fatigue, and Self-Care Behaviors","Inclusion Criteria:\n\n* Being 18 years of age or older\n\nBeing literate (able to read and write)\n\nHaving no significant hearing or visual impairment that prevents communication or cooperation\n\nReceiving treatment in the palliative care unit\n\nHaving a confirmed medical diagnosis of cancer\n\nHaving a Glasgow Coma Scale (GCS) score of 10 or higher\n\nBeing able to communicate via telephone and SMS for post-discharge follow-up\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 3 or below\n\nHaving an ECOG Performance Status Scale score of 3 or below\n\nHaving a Hemoglobin (Hb) value of 8 gm\u002FdL or higher\n\nVolunteering to participate in the study and providing informed consent\n\nExclusion Criteria:\n\n* Currently practicing or having recently practiced Progressive Muscle Relaxation (PMR) or deep breathing exercises actively\n\nHaving a primary respiratory system disease diagnosis (such as COPD, asthma, or pneumonia)\n\nHaving a medical diagnosis of dementia, agitation, or delirium\n\nReceiving Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) support\n\nBeing on active antipsychotic or sedative medical treatment\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 4 or higher",{"count":188,"type":21},90,[24],"The purpose of this study is to evaluate the effects of Progressive Muscle Relaxation (PMR) exercises and deep breathing exercises on dyspnea, fatigue, and self-care behaviors among cancer patients receiving palliative care. Advanced-stage cancer patients frequently experience debilitating symptoms such as shortness of breath (dyspnea) and severe fatigue, which significantly impair their functional capacity and daily self-care activities. Participants in this study will be assigned to either a progressive muscle relaxation intervention group or a structured deep breathing exercise group. The study aims to determine whether these non-pharmacological relaxation techniques can effectively reduce the severity of dyspnea and fatigue, thereby improving the patients' overall self-care behaviors and physical comfort in a palliative care setting.",[80,192,27,193,194],"Fatigue","Progressive Muscle Relaxation","Patient",[27,196,193,197,198,199,200,201],"Cancer Patients","Deep Breathing Exercises","Dyspnea Management","Cancer-Related Fatigue","Self-Care Behaviors","Randomized Controlled Trial","2026-05-30",{"date":204,"type":33},"2026-06-03",{"date":206,"type":33},"2026-01-01",{"date":208,"type":21},"2026-12",{"name":210,"class":40},"Ankara University",4,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100640213","effectiveness-and-implementation-of-the-dinknesh-digital-palliative-care-tool-in-ethiopia-100640213","NCT07574281","Effectiveness and Implementation of the DINKNESH Digital Palliative Care Tool in Ethiopia","Effectiveness and Implementation Determinants of the DINKNESH App Compared to Paper-Based Assessment Tools for Palliative Care: A Mixed-Methods Cluster Randomized Trial in Addis Ababa, Ethiopia","Inclusion Criteria\n\n* For patients(Quantitative Part):\n\n  * Adults aged 18 years or older\n  * Currently diagnosed with one or more chronic conditions and receiving home-based follow-up care from a participating Family Health Team within the catchment area of a selected study cluster\n  * Willing to provide verbal informed consent, or has a primary caregiver willing to provide proxy consent\n* For healthcare workers:\n\n  * Staff members of the Family Health Team at the selected clusters\n  * Involved in delivering or supervising palliative care services during the study period\n  * For the qualitative part: Participated in the DINKNESH App implementation process and is willing to participate in a Focus Group Discussion (FGD)\n\nExclusion Criteria\n\n* For patients\n\n  * Patients whose clinical condition prevents both self-participation and proxy participation in the assessment process\n  * Patients already formally identified and referred for palliative care prior to the study period\n* For healthcare workers:\n\n  * Staff members planning to be absent for more than 1 day during the six-week active study period\n  * Healthworkers not present during the training session",{"count":220,"type":21},1440,[24],"The goal of this clinical trial is to learn if a digital health app called DINKNESH is effective for palliative care identification compared to traditional paper-based assessment tools. It will also look at the factors that help or hinder the use of this app in primary care settings.\n\nThe main questions it aims to answer are:\n\nDoes the DINKNESH app improve palliative care assessments compared to paper forms?\n\nWhat are the main barriers and facilitators for Health Extension Workers when using the app in their daily work?\n\nWe will compare the DINKNESH app to standard paper-based tools to see if digital tools improve clinical assessment and implementation.\n\nParticipants will:\n\nBe assessed for palliative care needs using either the DINKNESH mobile app or standard paper forms.\n\nReceive routine follow-up care as determined by their health provider.\n\n(For health workers): Participate in interviews or surveys to discuss their experience using the assigned assessment tool.",[27],"2026-05-04",{"date":226,"type":33},"2026-05-07",{"date":228,"type":21},"2026-04",{"date":230,"type":21},"2026-05",{"name":232,"class":40},"Addis Ababa University",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100636569","virtual-reality-therapy-for-improving-caregiver-and-patient-quality-of-life-in-home-based-palliative-care-in-saudi-arabia-100636569","NCT07567391","Virtual Reality Therapy for Improving Caregiver and Patient Quality of Life in Home-Based Palliative Care in Saudi Arabia","Virtual Reality Nature Therapy for Palliative Patients and Caregivers in Saudi Arabia: A Randomized Controlled Trial to Support Quality of Life and Cultural Adaptation","VIRTIC-Hajj","Inclusion Criteria:\n\n* Adult patients (≥18 years) receiving palliative care in Saudi Arabia\n* Primary family caregivers living with and providing daily care to the patient\n* Ability to provide informed consent\n* Fluent in Arabic\n\nExclusion Criteria\n\n* Severe cognitive impairment or psychiatric conditions that prevent use of VR\n* History of epilepsy or vestibular disorders\n* Inability to understand or follow instructions for using VR equipment",{"count":242,"type":21},100,[24],"This randomized controlled trial evaluates the efficacy of a culturally adapted virtual reality (VR) nature therapy intervention aimed at improving the quality of life (QOL) and emotional well-being of palliative patients and their family caregivers in Saudi Arabia. The study involves immersive VR sessions depicting natural environments, including Saudi-specific landscapes, delivered to patient-caregiver dyads at home. Outcomes include self-reported QOL measures, psychophysiological parameters, and qualitative feedback.",[246,116,27,247],"Virtual Reality","Caregivers",[246,27,116,247],"2026-05-03",{"date":251,"type":33},"2026-05-05",{"date":253,"type":21},"2026-10-20",{"date":255,"type":21},"2027-09-01",{"name":257,"class":40},"University of Bisha",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":266,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":66},"100612017","effectiveness-of-the-mindful-compassion-care-program-for-healthcare-professionals-in-oncology-and-palliative-care-100612017","NCT07248111","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care: a Randomized Controlled Trial With a Qualitative Component","MCCP","Inclusion Criteria:\n\n* Being a healthcare professional (physicians, nurses, or nursing assistants) involved in the clinical management of cancer patients across different care settings and illness phases.\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* HPs must not have attended MBSR or other mindfulness\u002Fcompassion-based interventions, including in educational or clinical settings, involving activities similar to those in the present study in the previous six months.",true,{"count":268,"type":21},160,[24],"This randomized controlled trial aims to evaluate the effectiveness of the Mindful Compassion Care Program (MCCP), a mindfulness- and compassion-based intervention designed to enhance the emotional and professional well-being of healthcare professionals (HPs). The study adopts a multi-center, open-label, randomized, parallel-group, superiority design and includes HPs (physicians, nurses, and nursing assistants) involved in the clinical care of cancer patients across different settings and disease phases. Eligible participants must not have attended MBSR or other mindfulness-\u002Fcompassion-based interventions in the preceding six months.\n\nThe RCT has a primary objective of assessing the MCCP's effectiveness in increasing positive emotions and reducing negative emotions among HPs working in oncology and palliative care. Secondary objectives include evaluating improvements in professional quality of life and self-compassion. After providing informed consent, HPs will be randomized to receive either the MCCP (experimental group) or no intervention (control group).",[272,27,273],"Professional Quality of Life","Oncology",[275,276,277,278,279],"mindfulness","self-compassion","emotional regulation","supportive care","mental health promotion","2026-04-28",{"date":282,"type":33},"2026-04-29",{"date":284,"type":21},"2027-12",{"date":286,"type":21},"2028-01",{"name":288,"class":289},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":41},"100587860","promoting-palliative-care-for-people-with-heart-failure-100587860","NCT06933875","Promoting Palliative Care for People With Heart Failure","Promoting Palliative Care for People With Heart Failure: The P3HF Pilot Study","P3HF","Inclusion Criteria:\n\nHealthcare providers must meet the following criteria:\n\n* Are an attending physician, fellow, or resident, advanced practice nurse, or physician associate\n* Has ordering privileges\n* Are members of one of the hospitals' admitting teams (e.g., hospitalist service, cardiology service)\n* Anticipate employment at one of the two study sites for the 15-month trial period.\n\nOr\n\n* Palliative care team member\n* Hospital administrator\u002Fquality and safety personnel\n\nPatients of providers enrolled in the study must meet the following criteria for heart failure during hospitalization:\n\n* Age 18 years of age or older\n* N-terminal pro-B-type natriuretic peptide values of \\>500 pg\u002Fml\n* Received intravenous diuretics within 24 hours of admission.\n\nExclusion Criteria:\n\n* Pregnant at the time of admission.",{"count":299,"type":21},2260,[24],"This project will develop and test a novel clinical decision support tool (CDS) that encourages timely referral to palliative care for people hospitalized with heart failure. This intervention will incorporate an existing, validated 1-year mortality risk model into a CDS to deliver prognostic information and evidence-based decision support at the point of care. Thus, this research may lead to improved care-concordant and goal-directed care for people with heart failure.",[303,27],"Heart Failure","2026-04-24",{"date":306,"type":33},"2026-04-30",{"date":308,"type":21},"2026-05-22",{"date":310,"type":21},"2027-08-30",{"name":312,"class":40},"Yale University",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":321,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":211},"100507142","phase-2-lysergic-acid-diethylamide-lsd-in-palliative-care-100507142","NCT05883540","Lysergic Acid Diethylamide (LSD) in Palliative Care","Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","LPC","Inclusion Criteria:\n\n* Age ≥ 22 years.\n* Advanced or End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years\n* Sufficient understanding of the study procedures and risks associated with the study.\n* Participants must be willing to adhere to the study procedures and sign the consent form.\n* Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration.\n* Participants must complete an actual \"Emergency Medical Directive\"\n* Participants with central nervous system (CNS) involvement of cancer are eligible if the following apply:\n\n  * treated and stable CNS lesion(s) OR untreated but asymptomatic\u002Fstable lesions, defined as clinically and\u002For radiologically stable for ≥ 4 weeks before screening\n  * no seizures within ≥ 4 weeks; if on antiepileptic medication: stable dose ≥ 4 weeks and no relevant drug-drug interactions expected\n  * no requirement for high-dose corticosteroids, defined as ≤10 mg prednisone equivalent per day on a stable or decreasing dose\n  * no leptomeningeal metastases\n  * no concomitant therapeutic anticoagulation\n\nExclusion Criteria:\n\n* Life expectancy \\< 12 weeks\n* Known hypersensitivity to LSD\n* Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period.\n* Current use of a potent drug CYP2D6 inhibitor\n* Women who are pregnant or nursing or intend to become pregnant during the course of the study.\n* Somatic disorders including CNS involvement of cancer, untreated epilepsy with a history of generalized grand-mal seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects.\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* concomitant diagnosis of past or present psychotic disorder, first-degree relative with psychotic disorders\n* concomitant diagnosis of past or present bipolar disorder\n* current delirium\n* substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety).\n* Weight \\< 45 kg\n* Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator.\n* CNS involvement of cancer if\n\n  * CNS disease is unstable or high-risk, including clinically and\u002For radiologically progressive lesions, signs of raised intracranial pressure, radiologically uncontrolled edema, need for escalating corticosteroid doses, or any neurological condition judged to pose too excessive risk.\n  * CNS-directed therapy (surgery and\u002For radiation) within ≤ 4 weeks","22 Years",{"count":323,"type":21},60,[109],"Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects.\n\nObjective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.",[27,327,328,329,330,331,116,87,332,333],"Pain","Anxiety","Depression","Demoralization","Psychological Distress","Fear of Death","Existential Distress","2026-04-23",{"date":282,"type":33},{"date":337,"type":33},"2024-06-09",{"date":339,"type":21},"2028-05",{"name":341,"class":40},"University Hospital, Basel, Switzerland",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":357,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":66},"100634918","single-arm-monocentric-pilot-feasibility-study-on-an-interactive-virtual-reality-program-in-20-complex-in-clinic-palliative-care-patients-100634918","NCT07545928","Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients","ZENCTUARY_VR+","Inclusion Criteria:\n\n* Patient ≥ 18 years old, hospitalized at the USP - HUS\n* Estimated life expectancy ≥ 1 month (Pronopall score based on clinical data).\n* Montreal Cognitive Assessment (MoCA) scale score ≥ 26.\n* Able to understand the objective and risks of the study\n* VRISE score ≤ 25 after the VR familiarization procedure\n* Affiliation with the Social Security system or beneficiary of such social protection.\n* Signed consent from, able to understand and complete the questionnaires in French.\n\nExclusion Criteria:\n\n* Patients with psychiatric disease\n* Patients under court protection\n* Uncontrolled epilepsy\n* Visual impairments (lack of binocular vision, blindness) and\u002For hearing impairments (deafness) preventing the use of virtual reality",{"count":350,"type":21},20,[24],"Palliative care patients frequently face a \"symptom cluster\" of pain (up to 96%), fatigue (up to 90%), and anxiety (up to 79%), which severely degrades their quality of life in their final months.The study is built on the concept of passive exposure therapy (VREP), which engages multiple senses to distract the brain from pain signals. By creating an \"immersive distraction\" or a \"flow state,\" VR can activate the brain's reward networks and reduce activity in areas associated with pain perception. Unlike most existing VR research in palliative care which uses \"passive\" VR (like watching a 360-degree video), this study uses interactive VR. Patients can perform simple actions-like grabbing or dropping virtual objects-within a calming natural environment, which may better support their sense of autonomy and dignity. Because this is a pilot study, the \"Go\u002FNo-Go\" decision for future larger trials depends on a strict composite of three factors:\n\n* Adherence: The patient must complete at least 11 out of 14 planned daily sessions.\n* Duration: Each session must average at least 7.5 minutes of usable VR exposure.\n* Tolerance: The patient must experience no device-related serious adverse events and maintain a high average tolerance score (VRISE score ≥ 25).",[27,354,328,355,356,331],"Refractory Pain","Depression Disorders","Fatigue, Mental",[358,359,360,361,362,363,364],"palliative care","end-of-life care","refractory pain","Interactive Virtual Reality","Immersive Technology","Virtual Reality Exposure Therapy (VRET)","Cybersickness in Palliative Care","2026-04-15",{"date":367,"type":33},"2026-04-22",{"date":369,"type":21},"2026-09-01",{"date":371,"type":21},"2027-03-01",{"name":373,"class":40},"University Hospital, Strasbourg, France",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":66},"100630766","palliative-and-supportive-care-to-help-people-with-arthritis-to-live-well-enrich-100630766","NCT07491939","Palliative and Supportive Care to Help People With Arthritis to Live Well (ENRICH)","Exploring Perspectives on Palliative and Supportive Care, to Inform Recommendations to Help People Live Well With Inflammatory Arthritis Throughout the Disease Course (ENRICH)","ENRICH","Inclusion Criteria:\n\n* Adults (\\> 18 years) with a diagnosis of arthritis (Rheumatoid, Psoriatic or Juvenile Idiopathic) or Axial Spondyloarthritis\n* able to understand and communicate in verbal and written English (or via an interpreter nominated by the participant or provided via an agency by the research team)\n* in receipt, or not in receipt of Palliative Care services\n* access to Microsoft Teams or a telephone\n* consent to sharing preferred contact details\n\nExclusion Criteria:\n\n* Cognitive impairment that impedes communication\n* non-English speaker (should an interpreter not be available).",{"count":76,"type":21},"OBSERVATIONAL","Palliative Care (PC) focuses on maximising quality of life and care for patients and their families in the last 1000 days of life. Supportive Care (SC) is provided earlier in life for people with a long-term health condition.\n\nPeople living with inflammatory arthritis, (such as rheumatoid arthritis) can experience ongoing pain, stiffness, limitations in their joints, and intrusive fatigue. This impacts daily living activities and emotional well-being. People with inflammatory arthritis would value support to manage symptoms across the course of their disease. They would like PC healthcare professionals (HCPs) to understand their conditions better, so they can live well to the end of their lives.\n\nAims:\n\nThe investigators will explore the potential role of Palliative and Supportive Care (PSC) for people with inflammatory arthritis. The investigators will describe any unmet patient need. The investigators will develop clinical and research recommendations to help people with inflammatory arthritis live well over the course of their disease.\n\nPlan:\n\nThe investigators research will be conducted in three studies:\n\nStudy 1: The investigators will conduct 1:1 online interviews with people with inflammatory arthritis to understand how PSC is perceived by them, and what their views are on how PSC may support them to live well.\n\nStudy 2: The investigators will send an online survey to Rheumatologists, Primary Care, Community and PC HCPs, to understand:\n\n* if and how they work together currently;\n* their views on the role of PSC supporting people with inflammatory arthritis to live well.\n\nStudy 3: The investigators will conduct online focus groups with volunteers from Studies 1 and 2, representatives from relevant national charities\u002Forganisations, and people who commission health services. Together the group will discuss the research findings and agree:\n\n* what the gap in patient care is;\n* recommendations for future clinical practice and research;\n* the key areas of importance for patients which should be measured in future work",[386,27],"Inflammatory Arthritis",[388,27],"Inflammatory arthritis","2026-03-24",{"date":391,"type":33},"2026-03-25",{"date":393,"type":33},"2026-02-19",{"date":395,"type":21},"2027-04",{"name":397,"class":40},"Dorothy House Hospice",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":415,"leadSponsor":416,"locationsCount":66},"100630321","complex-decisions-regarding-antithrombotic-therapy-the-quiet-study-100630321","NCT07486154","Complex Decisions Regarding Antithrombotic Therapy: the QUIET Study","QUIET","Inclusion Criteria:\n\n* Affiliation, as a physician, with one of the main Italian scientific societies actively involved in the management of antithrombotic therapy in patients referred to Palliative Care\n* Electronic informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Failure to complete or incomplete completion of the questionnaire.",{"count":49,"type":21},"\"Complex decisions regarding antithrombotic therapy: the QUIET study\" is a monocentric observational study without drug intervention, conducted through the administration of a questionnaire (survey).The aim of this study is to explore, through the administration of a questionnaire (survey) consisting of hypothetical clinical cases, the approach of physicians regarding the prescription, continuation, or discontinuation of antithrombotic therapies in patients referred to Palliative Care.",[27],[409,410,358],"antithrombotic therapy","end of life","2026-03-17",{"date":413,"type":33},"2026-03-20",{"date":228,"type":21},{"date":395,"type":21},{"name":417,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":434,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":66},"100629062","multidisciplinary-care-pathway-tailored-on-frailty-in-cancer-patients-referred-to-outpatient-palliative-care-100629062","NCT07469761","MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care","MISTRAL","Inclusion Criteria:\n\n* diagnosis of advanced\u002Fmetastatic cancer\n* age \\> 18\n* Eastern Cooperative Oncology Group (ECOG) performance status ≥2\n* prognostic clinical prediction \\>1 month.\n\nExclusion Criteria:\n\n* Serious medical or psychiatric illness that can interfere with informed consent and participation in this clinical study\n* any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.",{"count":76,"type":21},[24],"The goal of this clinical trial is to learn whether a structured, Patient-Reported Outcome Measures (PROMs)-tailored palliative care pathway improves clinical outcomes and care experience in adults with advanced cancer referred to outpatient palliative care.\n\nPatients with advanced cancer often experience multiple symptoms and complex needs. Standard outpatient palliative care is usually guided by clinical judgment on patient-reported questionnaires. In this study, researchers aim to test whether a more structured approach, based on predefined cut-offs from PROMs, can improve symptom control, satisfaction with care, and use of healthcare resources. The main questions the study aims to answer are:\n\nDoes a structured, PROM-driven palliative care pathway reduce symptom burden and psychological distress compared with usual care? And through this, to improve patients' and caregivers' satisfaction with care or reduce emergency room visits, hospital admissions, healthcare costs, and aggressive treatments near the end of life?\n\nResearchers will compare two groups:\n\nControl group: Participants will receive standard outpatient palliative care. PROMs are collected as usual, but without predefined cut-offs or structured intervention checklists.\n\nExperimental group: Participants will receive a structured palliative care pathway tailored to symptoms\u002Fneeds identified at baseline using PROM cut-offs. Specific multidisciplinary interventions are activated according to identified needs.",[27,429,430,431,432,80,433],"Palliative Care, Health Services","Patient Reported Outcome (PRO)","Patient Reported Outcome Measurements","Frailty","Outpatient",[435,433,27,436,432,437],"Patient Reported Outcome Measurements (PROMs)","Advanced cancer","Palliative Care intervention","2026-03-09",{"date":440,"type":33},"2026-03-13",{"date":442,"type":33},"2025-11-02",{"date":444,"type":21},"2027-02-28",{"name":446,"class":40},"Augusto Caraceni",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":211},"100561314","improving-needs-among-older-adults-100561314","NCT06588556","Improving Needs Among Older Adults","Improving Needs Among Older Adults: the ICUconnect 2 Primary Palliative Care RCT","ICUconnect 2","Inclusion Criteria:\n\nPatients (who are not interviewed but whose characteristics prompt enrollment of family members)\n\n1. Adult aged ≥18 years\n2. Managed in an adult medical, cardiac, trauma, surgical, or neurological ICU\n3. Serious acute illness associated with a need for invasive mechanical ventilation\n4. ICU team expect patient to require mechanical ventilation for 2 or more days\n\nFamily members\n\n1. Adult aged ≥18 years\n2. Family member: self-described as the individual (related or unrelated) who provides the most support and with whom the eligible patient has a significant relationship (Society of Critical Care Medicine definition of family; Davidson J, et al. Crit Care Med, 45:103-128; 2017)\n\nICU clinicians\n\n1. Adult aged ≥18 years\n2. ICU clinician: ICU attending caring for the eligible patient on the day of family member informed consent\n\nExclusion Criteria:\n\nPatients\n\n1. Death or full comfort care plan expected within 24 hours by ICU attending or fellow physician Rationale: measurable intervention effect unlikely\n2. Palliative care consultative team and\u002For palliative care specialists are currently involved in the patient's care.\n\n   Rationale: this would dilute the intervention's effect.\n3. ICU length of stay \\>4 days during current ICU admission. Rationale: this would dilute intervention effect by widening the timeframe of family-clinician interactions and limiting standardization.\n\n6\\. Imprisoned person. Rationale: this is a vulnerable population.\n\nFamily members\n\n1. Low palliative care need burden (i.e., NEST scale score \\\u003C15) at baseline. Rationale: if there are very low baseline needs, the intervention cannot impact the primary outcome measure (i.e., NEST).\n2. Lack of English or Spanish fluency, operationalized as need for a translator to understand medical forms or participate in medical discussions.\n\n   Rationale: the app has not been translated into other languages; also, many outcome measures aren't validated in languages other than English and Spanish.\n3. Endorsement of suicidal ideation (i.e., PHQ-9 suicidality item) at the time of baseline data collection.\n\n   Rationale: this indicates a serious level of distress that will require professional assistance beyond that provided by the intervention (or control).\n4. Patient regains decisional capacity after informed consent but before the first family meeting. Rationale: as in our past ICU-based studies, this circumstance (the entry of the patient as a decision maker), would substantially change the nature of the interactions of family members and clinicians.\n5. The ICU clinician changes from a consented clinician to a non-consented clinician before the first family meeting. Rationale: in this circumstance the intervention cannot be fully deployed.\n\nICU clinicians None",{"count":456,"type":21},350,[24],"Millions of older adults receive care in intensive care units (ICUs) annually. However, the quality and accessibility of ICU-based palliative care is highly variable across hospitals and clinicians, due in part to specialists' limited workforce and geographic inconsistency. To address these gaps, the investigators developed an innovative mobile app-based primary palliative care intervention called ICUconnect. ICUconnect facilitates families' and patients' self-report of actual palliative care needs across all core domains of palliative care quality, provides ICU clinicians with a scalable digital infrastructure for coordinating consistent and personalized needs-targeted care, and provides a variety of informational supports relevant to each user's role. In this RCT, the investigators will test ICUconnect vs. usual care control among 350 patient-family member dyads with elevated baseline levels of unmet palliative care need in a 4-site network serving a diverse population (Duke, Medical University of South Carolina, University of Alabama at Birmingham, Columbia).\n\nThe specific aims are to: (1) Test the efficacy of ICUconnect vs. usual care control in improving palliative care needs and other person-centered outcomes including psychological distress, (2) Determine participant characteristics associated with a greater treatment response using a heterogeneity of treatment effects approach, and (3) Ensure off-the-shelf intervention readiness for implementation using a mixed-methods integration of qualitative analysis of semi-structured trial participant interviews and quantitative RE-AIM implementation framework-informed trial data.",[460,27,461,462,463],"Critical Illness","Older Adults","Informal Caregivers","Care Delivery Model","2026-03-04",{"date":466,"type":33},"2026-03-06",{"date":468,"type":33},"2025-09-16",{"date":470,"type":21},"2028-12-31",{"name":472,"class":40},"Duke University",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":41},"100627230","palliative-care-intervention-to-improve-health-related-quality-of-life-for-patients-on-long-term-lvad-support-100627230","NCT07445932","Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support","The PALL-VAD Study: Palliative Care Intervention to Improve Health Related Quality of Life for Patients With Heart Failure on Long-Term LVAD Support: A Pilot, Prospective, Randomized Trial","PALL-VAD","Inclusion Criteria:\n\n* LVAD patients \\>= 18 years of age\n* \\>= 1 year post-LVAD implantation\n\nExclusion Criteria:\n\n* Listed for heart transplantation. Undergoing evaluation for heart transplantation, however, is not an exclusion.\n* Non-English speaking\n* Receiving outpatient palliative care in the last 6 months\n* Renal replacement therapy\n* Non-cardiac terminal illness\n* Women who are pregnant or planning to become pregnant\n* Inability to comply with study protocol and follow up\n* Inabilty to provide consent.\n* Cognitive impairment or intellectual disability that prohibits successful completion of the HRQoL scales or compliance with the study protocol and follow up.",{"count":188,"type":21},[24],"Background: While left ventricular assist device (LVAD) therapy improves survival in patients with advanced heart failure (AHF), unique LVAD-related burdens may impact health-related quality of life (HRQoL). Palliative care specialists are key members of the multidisciplinary care team for patients with long-term-LVAD (LT-LVAD), offering specialized, comprehensive, holistic care.\n\nProblem: A seminal study of palliative care in patients with heart failure (PAL-HF trial) demonstrated that outpatient palliative care improved HRQoL, depression, anxiety, and spiritual well-being compared to usual care. The impact of longitudinal palliative care on HRQoL in LT-LVAD patients is unknown.\n\nObjective: The investigators aim to conduct the first study examining a palliative care intervention to improve HRQoL among LT- LVAD recipients (patients who have lived with LT-LVAD for at least six months and are not heart transplant candidates) at two centers (MedStar Health and Inova) in the Mid-Atlantic Region. Given the demographics of the study institutions, the investigators anticipate a socioeconomically and racially diverse cohort of patients with subgroups who may disproportionately experience LVAD-related burdens relative to benefits.\n\nAims: The first aim is to assess baseline measures of HRQoL in LT-LVAD patients to understand differences in HRQoL across subgroups and multiple, understudied domains. The second aim is to test the feasibility and acceptability of a randomized, unblinded pilot study of a palliative care interdisciplinary intervention in this population.\n\nSignificance: Results of this study will inform the development of a large randomized controlled trial to test the effectiveness of palliative care intervention in improving HRQoL in LT-LVAD patients. If results are positive, this will revolutionize the post-LVAD treatment paradigm, by making palliative care integration the standard of care for longitudinal LT-LVAD patient management.",[485,486,487,27],"Advanced Heart Failure","Mechanical Circulatory Support","Left Ventricular Assist Device",[489,490,358],"advanced heart failure","left ventricular assist device","2026-02-25",{"date":493,"type":33},"2026-03-03",{"date":495,"type":21},"2026-03-01",{"date":371,"type":21},{"name":498,"class":40},"Medstar Health Research Institute",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":266,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":518,"leadSponsor":520,"locationsCount":66},"100617892","oral-health-in-palliative-care-a-survey-study-100617892","NCT07324525","Oral Health in Palliative Care: A Survey Study","Oral Health and Dental Care in Palliative Medicine: A Survey Study Among Patients and Members of the German Society for Palliative Medicine","OH-PAL","Inclusion Criteria:\n\n* consent-capable patients receiving palliative care\n* patients whose health status allows completion of a questionnaire\n* consent-capable members of the German Society for Palliative Medicine\n\nExclusion Criteria:\n\n* Participants under 18 years of age\n* Individuals who are unable or unwilling to provide informed consent",{"count":508,"type":21},151,"Oral health problems such as xerostomia or oral infections are common in palliative care patients and can significantly impair quality of life. Adequate dental care may contribute substantially to symptom control and well-being; however, oral health and dental services are often insufficiently integrated into palliative care practice. In addition, little is known about the level of awareness, knowledge, and interprofessional collaboration regarding oral health among palliative care professionals.\n\nThis prospective, non-interventional survey study aims to assess the relevance of oral health in palliative care by surveying both palliative care patients and healthcare professionals who are members of the German Society for Palliative Medicine. The study investigates patients' oral health status, oral health-related quality of life, and access to dental care, as well as professionals' knowledge, attitudes, and current practices related to oral health and dental care in palliative settings. The findings are intended to identify existing gaps and inform strategies for improved integration of dental expertise into palliative care.",[511,512,27,513],"Oral Health Care","Oral Health-Related Quality of Life","Palliative Care, Patient Care","2026-02-24",{"date":516,"type":33},"2026-02-27",{"date":514,"type":33},{"date":519,"type":21},"2026-06",{"name":521,"class":40},"University Medical Center Goettingen",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":266,"sex":17,"minAge":18,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":541,"locationsCount":4},"100625816","palliative-care-and-the-terminally-ill-adults-end-of-life-bill-100625816","NCT07427550","Palliative Care and The Terminally Ill Adults (End of Life) Bill","The Potential Impact of the Terminally Ill Adults (End of Life) Bill on the Professional Identity of Palliative Care Staff","Inclusion Criteria:\n\n* Palliative care staff, including Palliative nurses, Doctors and Consultants.\n* Registered with the appropriate professional registration body\n* Must have been in qualified position and working in palliative care for at least 6 months\n* Must have worked with palliative patients in the last three months\n* Fluency in English\n\nExclusion Criteria:\n\n* No direct contact with patients\n* Must be in a directly caring role within the team (does not include administrative or housekeeping staff).","80 Years",{"count":531,"type":21},6,"The current study aims to investigate the potential impact of the proposed Assisted Dying (Terminally Ill Adults (2024) Bill on Palliative care workers. Palliative care professionals across the Humber Health Partnership will be interviewed using semi-structured interview questions, with the intention of exploring the way they make sense of the potential implementation of the bill, particularly in relation to their professional identity. The research will be carried out in line with guidance for Interpretative Phenomenological Analysis (Smith, Flowers \\& Larkin, 2021), a research methodology which aims to explore how people make sense of their experience, often in response to a particular event.\n\nIt is hoped that the study will contribute to the ongoing discussions regarding how the bill should be implemented and offer potential insights into ways that hospitals may best support staff during the passing of the bill into law. The study will be sponsored by Hull University Teaching Hospitals Trust (HUTH).",[534,27],"Assisted Dying","2026-02-16",{"date":537,"type":33},"2026-02-23",{"date":495,"type":21},{"date":540,"type":21},"2027-05-01",{"name":542,"class":289},"Hull University Teaching Hospitals NHS Trust",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":550,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":561,"leadSponsor":563,"locationsCount":66},"100603958","early-phase-1-testosterone-supplementation-in-patients-in-best-supportive-care-impact-on-quality-of-life-100603958","NCT07143279","Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life","TestoSup","Inclusion Criteria:\n\n1. Male hypogonadal with total testosterone \\\u003C 231 ng\u002Fdl in best supportive care with no further therapeutic options and who do not wish to be reanimated.\n2. Age ≥ 18 years old\n3. Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure.\n\nExclusion Criteria:\n\n1. Untreated prostate cancer, given the risk of epiduritis.\n2. Known hypersensitivity reactions to the study drug or to any excipients.\n3. Known allergies to peanuts or soya.","MALE",{"count":350,"type":21},[553],"EARLY_PHASE1","This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone \\\u003C 231 ng\u002FdL) male subjects in best supportive care, with no further therapeutic options and no need for resuscitation.\n\nCurrently, testosterone formulations for intramuscular (IM) injection and subcutaneous injection as well as for oral and transdermal administration have been approved for androgen therapy. To date, injectable testosterone is the most commonly used formulation. To increase serum testosterone levels to the physiological range IM injections of testosterone every 2-3 weeks are required, which lead to supraphysiological peaks shortly after administration, followed by a sharp fall in levels thereafter. Testosterone levels before the next injection are frequently in the hypogonadal range. For this reason, Sustanon 250® (1 ml, IM) will be administered on day 0 after confirmation of hypogonadism by blood test and then every 15 days in this trial given the limited life expectancy of the subjects and to maximise the effect and benefit of testosterone supplementation.\n\nThe Edmonton questionnaire and ADL questionnaire will be completed before the injection on day 0 and then every 15 days at the time of injection until subject's death or if a subject is discontinued from the study treatment\u002Fprocedures for any other reasons than death. In parallel, the EQ-5D-3L questionnaire will be completed by a family member or a proxy.",[556,27],"Hypotestosteronism","2026-02-11",{"date":559,"type":33},"2026-02-13",{"date":557,"type":33},{"date":562,"type":21},"2027-11",{"name":564,"class":40},"Jules Bordet Institute",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":66},"100575416","attitudes-towards-deprescribing-medications-in-cancer-patients-and-impact-of-educational-intervention-by-a-clinical-pharmacist-100575416","NCT06771999","Attitudes Towards Deprescribing Medications in Cancer Patients and Impact of Educational Intervention by a Clinical Pharmacist","Attitudes Towards Deprescribing of Non-oncologic Medication in Cancer Pacient and the Impact of an Educational Intervention by a Clinical Pharmacist","Inclusion Criteria:\n\n* cancer patients in palliative treatment\n* ECOG 1-2\n\nExclusion Criteria:\n\n* cancer patients in curative treatment\n* ECOG 3-4\n* cognitive impairment",{"count":76,"type":21},[24],"Participation in this study consists in responding to some questions from two questionnaires in Romanian about how participants feel about deprescribing, participants' treatment and how participants understand medical information. After that, participants will receive a brochure and watch a video with some basic information about medications and participants' involvement in treatment decisions and in the next visit for cancer treatment participants will be asked to answer questions from one of the initial questionnaire.",[27,80],[358,577,578,579,580],"cancer","clinical pharmacist","educational intervention","rPATD",{"date":559,"type":33},{"date":583,"type":33},"2025-01-13",{"date":585,"type":21},"2027-04-30",{"name":587,"class":40},"Iuliu Hatieganu University of Medicine and Pharmacy",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100530922","deprescribing-perceptions-of-patients-living-with-advanced-cancer-100530922","NCT06193083","DEprescribing: Perceptions of PAtients Living With Advanced Cancer","DEprescribing: Perceptions of PAtients Living With Advanced Cancer. A Multicentre, Prospective Mixed Observational Study","DEPAL","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)\n* Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)\n* Hospitalized or in consultation\n* With at least one PIMs (identified using STOPPfrail 2)\n* Patient not having expressed opposition to participating in the study after receiving information from the physician.\n\nFor qualitative study patients :\n\n\\- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.\n\nExclusion Criteria:\n\n* Minor\n* Major under guardianship, protected person\n* Patient unable to speak or write French\n* Patient with impaired judgment, cognitive or sensory impairment that prevents him\u002Fher from receiving informed information, answering questionnaires or participating in a study interview.",{"count":597,"type":21},325,"Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.\n\nRecently, palliative care initiatives have been introduced, but without having studied the potential specificities of this population (younger, with a different care dynamic and life trajectory). It is important to better understand this population's perceptions of deprescribing in order to adapt tools\u002Factions to make these approaches more efficient.\n\nThe primary aim of this study is to investigate patients' perceptions of deprescribing in palliative cancer care, and the secondary aim is to investigate factors that may influence patients' attitudes and beliefs about deprescribing. At the same time, we will study the psychometric properties of the rPATD (Revised Patients' Attitudes Towards Deprescribing) in this population (a standardized questionnaire validated in geriatric medicine to assess patients' perceptions of deprescription).An ancillary study will be carried out to investigate the link between patients' health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health).\n\nTo meet our objectives, we will conduct a 3-year national, prospective, observational, multicenter study with an exploratory sequential mixed design. The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period). Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.\n\nThanks to the different results, we will improve our knowledge of the perception of deprescription in palliative oncology care, in order to develop approaches adapted to the specificities of our population to reduce polymedication and thus improve the quality of life of our patients and reduce the risks of iatrogenia.",[600,27,273],"Deprescribing",[600,172,273],"2026-02-09",{"date":557,"type":33},{"date":605,"type":33},"2024-02-28",{"date":607,"type":21},"2026-12-29",{"name":609,"class":40},"Nantes University Hospital",8,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":621,"briefSummary":622,"conditions":623,"keywords":628,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":66},"100621237","end-of-life-care-in-mechanically-ventilated-patients-impact-of-a-comprehensive-palliative-care-protocol-in-the-intensive-care-setting-100621237","NCT07368010","End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Palliative Care Protocol in the Intensive Care Setting","End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Training to Palliative Care in the Intensive Care Setting. A Multicenter Cluster Randomised Trial","ARREVE-3","Inclusion Criteria:\n\n* Patient:\n\n  * Age ≥ 18 years\n  * ICU admission for more than 48 hours\n  * Receiving invasive mechanical ventilation\n  * A documented decision to withdraw life-sustaining therapies, made through a multidisciplinary collegial process and communicated to the designated surrogate decision-maker, family, or relatives\n  * At least one visit from a relative prior to the decision to withdraw life-sustaining therapies\n  * Provision of informed consent for study participation, or, if the patient lacks decision-making capacity, consent obtained from a relative or legally authorized representative\n* Relative:\n\n  * Age ≥ 18 years\n  * Has received at least one medical update regarding the patient's clinical status from an ICU physician prior to the decision to withdraw life-sustaining therapies\n  * Has provided informed consent for study participation\n\nExclusion Criteria:\n\n* Patient:\n\n  * Presence of a tracheostomy\n  * Brain death or involvement in an organ donation procedure\n  * Absence of any visit from a relative\n  * Subject to legal guardianship or other legal protection measures\n  * Incarcerated patient\n  * Participation in another interventional research study focused on end-of-life care\n  * Pregnant or breastfeeding woman\n* Relative:\n\n  * Inability to understand or speak French\n  * Subject to legal guardianship or other legal protection measures",{"count":620,"type":21},720,[24],"The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made. This cluster-randomized controlled trial compares protocol-based care with usual practice across participating centers. The intervention includes comprehensive guidance on symptom management, sedation, nursing care, withdrawal procedures, and family support, supported by standardized staff training. The primary endpoint is adherence to recommended end-of-life practices, while secondary outcomes assess patient comfort, communication with relatives, and the impact on families and healthcare professionals",[27,624,625,626,627],"Withdrawal of Life Support","Intensive Care Medicine","Sedation","Dying Process",[629,630,631,632,633,634,635,358],"End of life","intensive care medicine","mechanical ventilation","organ support","withdrawal","life support","sedation","2026-01-20",{"date":638,"type":33},"2026-01-26",{"date":640,"type":21},"2026-01-10",{"date":642,"type":21},"2029-01-10",{"name":609,"class":40},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":659,"leadSponsor":661,"locationsCount":66},"100621235","a-feasibility-study-of-death-education-intervention-for-family-caregivers-of-advanced-cancer-patients-100621235","NCT07367984","A Feasibility Study of Death Education Intervention for Family Caregivers of Advanced Cancer Patients","Death Education Intervention for Family Caregivers of Advanced Cancer Patients: a Mixed-methods Feasibility Study","Inclusion Criteria for patients:\n\n* Age 18 years or older;\n* The patient with pathologically confirmed stage III or IV cancer;\n* The patient has initiated any systemic anti-cancer therapy (e.g.,chemotherapy, immunotherapy, targeted therapy, endocrine therapy) and has completed the first treatment administration\u002Fcycle and commenced the next planned administration\u002Fcycle;\n* The patient is assessed by the doctor as having an estimated life expectancy of ≥3 months; and\n* The patient is aware of their advanced cancer diagnosis.\n\nExclusion Criteria for patients:\n\n-The patient has no primary family caregiver during the study period.\n\nInclusion Criteria for family caregivers:\n\n* Age 18 years or older;\n* The caregiver is identified by the patient as the primary family caregiver (e.g., spouse, adult child, parent, or other relative);\n* The caregiver has been regularly involved in caregiving for the patient in the past month, and is expected to continue providing support over the next two months (e.g., daily care, accompaniment, involvement in medical communication\u002Fdecision-making, and financial support);\n* Since taking on the primary caregiving role, the caregiver reports the frequency of talking about death\u002Fdying with the patient as \"Never\" or \"Rarely\" (from: Never \u002F Rarely \u002F Sometimes \u002F Often \u002F Very often);\n* The caregiver perceives a need for guidance and support in communicating with the patient about death-related matters; and\n* The caregiver has basic Chinese literacy (reading and writing) to understand the intervention content and complete written tasks.\n\nExclusion Criteria for family caregivers:\n\n* Paid or professional caregivers who receive financial compensation for providing caregiving services;\n* The caregiver provides financial support only, without regular contact with the patient;\n* The caregiver has significant cognitive impairment that would affect understanding the intervention and completing the study;\n* The caregiver has severe psychiatric symptoms that would affect understanding the intervention and completing the study;\n* The caregiver has significant communication difficulties that would affect understanding the intervention and completing the study;\n* The caregiver is unable to complete the 4-week intervention due to physical limitations (e.g., mobility restrictions preventing attendance at intervention sessions);\n* The caregiver has practical constraints that would prevent completion of the 4-week intervention or follow-up assessments (e.g., expected prolonged travel during the intervention period or inability to complete assessments as scheduled); and\n* The caregiver is currently receiving other structured psychological intervention or psychotherapy that is likely to affect study outcomes.",{"count":106,"type":21},[24],"Advanced cancer is the leading cause of death in the world and China. Family caregivers, as the closest individuals to advanced cancer patients, suffer from a range of psychological and spiritual issues due to patients' impending death. Various types of death education interventions have been developed to assist individuals in understanding the meaning of life and death and adapting to dying to address psychological and spiritual issues. However, these interventions have predominantly focused on advanced cancer patients only, with a significant gap in support for family caregivers.\n\nA mixed methods feasibility study will be conducted. A convenience sample of at least 30 family caregivers will be recruited. Participants will receive four 60-minute sessions, flexibly scheduled within a four-week period according to each participant's conditions. The researcher will be trained to deliver the intervention through individual face-to-face sessions in the oncology ward meeting room of the same hospital in phase I. The primary outcome will be feasibility (time to complete the recruitment, eligibility rate, recruitment rate, retention rate, attendance rate, acceptability rate). Secondary outcomes will be measured for preliminary intervention effectiveness on family caregivers' communication with patients on death, anxiety, depression, spiritual well-being, attitudes towards death, and quality of life after collecting the demographic information and written consent forms, and post-intervention. A descriptive qualitative evaluation will be conducted with 12 family caregivers to explore their experience of participating in the intervention by another researcher. The qualitative data in phase II will be audio-taped and transcribed verbatim and analysed using NVivo 14 through thematic analysis. The quantitative data will be entered in SPSS version 29.0. Descriptive statistics will be used to summarise the profiles of participants and outcomes.",[27,655,656],"Advanced Cancer","Family Caregivers",{"date":638,"type":33},{"date":495,"type":21},{"date":660,"type":21},"2026-08-31",{"name":662,"class":40},"The Hong Kong Polytechnic University"]